Role of SCARF1 in Human Lupus

SCARF1 在人类狼疮中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Efficient detection and clearance of apoptotic cells is essential in the maintenance of tolerance and tissue homeostasis. We recently identified the scavenger receptor expressed on endothelial cells-1 (SCARF1) as the receptor for apoptotic cells on dendritic cells via interactions with C1q/phosphatidylserine complexes on the dead cells (Ramirez-Ortiz et.al.; Nature Immunology). Loss of SCARF1 results in impaired uptake of apoptotic cells in vitro and in vivo, with accumulation of cell corpses in tissues and blood. Consequently, SCARF1 deficient mice develop lupus-like autoimmune disease. In this application, we propose to investigate the role of human SCARF1 in the onset and development of SLE. This is the next logical step in understanding the role of SCARF1 in apoptotic cell clearance, maintenance of tolerance and prevention of autoimmunity. We propose to: 1) Determine whether SCARF1 expression is dysregulated in SLE patients resulting in defects in apoptotic cell recognition and clearance by qRT-PCR, flow cytometry and ImageStream; 2) Define the interactions between SCARF1 with apoptotic cells via biochemical and imaging techniques; 3) Characterize the contribution of SCARF1 activation by C1q and/or apoptotic cells in dendritic cell signaling, maturation and antigen presentation using techniques such as T cell proliferation assay, Luminex analysis of cytokine secretion and confocal imaging techniques. Our preliminary data using cells from healthy volunteers shows that SCARF1 is highly expressed on monocytes and dendritic cells. We anticipate that SCARF1 expression will be downregulated on immune cells of SLE patients, exacerbating and/or accounting for the increased numbers of circulating apoptotic cells found in these patients. The etiology of SLE is unclear, but it is known that development of the disease results from a break in self-tolerance due to deregulated apoptosis or removal of cell corpses. Understanding the role of human SCARF1 in the processes of apoptotic cell recognition and clearance will provide new insight into the regulation of autoimmunity and could lead to the development of new and improved treatment for patients suffering from SLE.
描述(由申请方提供):有效检测和清除凋亡细胞对于维持耐受性和组织稳态至关重要。我们最近鉴定了内皮细胞上表达的清道夫受体-1(SCARF 1)作为树突细胞上凋亡细胞的受体,其通过与死细胞上的C1 q/磷脂酰丝氨酸复合物相互作用(Ramirez-Ortiz等; Nature Immunology)。SCARF 1的缺失导致体外和体内凋亡细胞的摄取受损,细胞尸体在组织和血液中积累。因此,SCARF 1缺陷型小鼠发展成狼疮样自身免疫性疾病。在本申请中,我们提出研究人SCARF 1在SLE发病和发展中的作用。这是理解SCARF 1在凋亡细胞清除、维持耐受性和预防自身免疫中的作用的下一个合乎逻辑的步骤。我们建议:1)通过qRT-PCR、流式细胞术和ImageStream确定SLE患者中SCARF 1表达是否失调导致凋亡细胞识别和清除缺陷; 2)通过生物化学和成像技术确定SCARF 1与凋亡细胞之间的相互作用; 3)表征C1 q和/或凋亡细胞对SCARF 1活化在树突细胞信号传导中的贡献,使用T细胞增殖测定、细胞因子分泌的Luminex分析和共聚焦成像技术等技术进行成熟和抗原提呈。我们使用来自健康志愿者的细胞的初步数据显示,SCARF 1在单核细胞和树突状细胞上高度表达。我们预计,SCARF 1表达将下调SLE患者的免疫细胞,加剧和/或占这些患者中发现的循环凋亡细胞的数量增加。SLE的病因尚不清楚,但已知疾病的发展是由于失调的细胞凋亡或细胞尸体的去除导致的自身耐受性的破坏。了解人SCARF 1在凋亡细胞识别和清除过程中的作用将为自身免疫调节提供新的见解,并可能导致开发新的和改进的SLE患者治疗方法。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Redirection to the bone marrow improves T cell persistence and antitumor functions.
  • DOI:
    10.1172/jci97454
  • 发表时间:
    2018-05-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Khan AB;Carpenter B;Santos E Sousa P;Pospori C;Khorshed R;Griffin J;Velica P;Zech M;Ghorashian S;Forrest C;Thomas S;Gonzalez Anton S;Ahmadi M;Holler A;Flutter B;Ramirez-Ortiz Z;Means TK;Bennett CL;Stauss H;Morris E;Lo Celso C;Chakraverty R
  • 通讯作者:
    Chakraverty R
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zaida Gisela Ramirez-Ortiz其他文献

Zaida Gisela Ramirez-Ortiz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zaida Gisela Ramirez-Ortiz', 18)}}的其他基金

Role of SCARF1 in removal of apoptotic debris and protection against autoimmunity
SCARF1 在清除细胞凋亡碎片和防御自身免疫方面的作用
  • 批准号:
    10409829
  • 财政年份:
    2021
  • 资助金额:
    $ 9.02万
  • 项目类别:
Role of SCARF1 in removal of apoptotic debris and protection against autoimmunity
SCARF1 在清除细胞凋亡碎片和防御自身免疫方面的作用
  • 批准号:
    10288804
  • 财政年份:
    2021
  • 资助金额:
    $ 9.02万
  • 项目类别:
Role of SCARF1 in Human Lupus
SCARF1 在人类狼疮中的作用
  • 批准号:
    8883392
  • 财政年份:
    2014
  • 资助金额:
    $ 9.02万
  • 项目类别:
Role of SCARF1 in Human Lupus
SCARF1 在人类狼疮中的作用
  • 批准号:
    8762787
  • 财政年份:
    2014
  • 资助金额:
    $ 9.02万
  • 项目类别:
Role of SCARF1 in Human Lupus
SCARF1 在人类狼疮中的作用
  • 批准号:
    9238453
  • 财政年份:
    2014
  • 资助金额:
    $ 9.02万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 9.02万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 9.02万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 9.02万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 9.02万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 9.02万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 9.02万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 9.02万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 9.02万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 9.02万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 9.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了